These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34840217)

  • 1. Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
    Yamada T; Kashiwagi T; Sakai Y
    J Nippon Med Sch; 2022 Aug; 89(4):360-367. PubMed ID: 34840217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
    Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
    Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
    Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D
    Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease.
    Guan H; Zheng Y; Zhou X; Xu Y; Fu C; Xiao J; Ye Z
    BMC Nephrol; 2020 Jul; 21(1):290. PubMed ID: 32698778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
    Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
    Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
    Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
    Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of total saponin of dioscorea on uric acid excretion indicators in chronic hyperuricemia rats].
    Chen GL; Wu S; Na S; Li L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Jan; 34(1):75-80. PubMed ID: 24520793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
    Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
    Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia.
    Pingali U; Nutalapati C; Koilagundla N; Taduri G
    BMC Complement Med Ther; 2020 Sep; 20(1):281. PubMed ID: 32933504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
    Zhang X; Wan D; Yang G; Peng Q; Wang X
    Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
    Nata N; Ninwisut N; Inkong P; Supasyndh O; Satirapoj B
    Sci Rep; 2023 Aug; 13(1):13494. PubMed ID: 37596359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
    Yang H; Li R; Li Q; Yan T; Li Y; Huang Q; Uchida S; Chang W
    Int Urol Nephrol; 2023 May; 55(5):1343-1352. PubMed ID: 36534221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
    Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW
    Nephron; 2017; 135(1):61-71. PubMed ID: 27701176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
    Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
    Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.